Alkermes plc. Selling and Marketing Expense
Alkermes plc. (ALKS) reported Selling and Marketing Expense of $154.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-07-28
- Alkermes plc. selling and marketing expense for the quarter ending 2026-06-30 was $154.36M, a 27.39% increase year-over-year.
- Alkermes plc. selling and marketing expense for the quarter ending 2026-03-31 was $155.56M, a 26.54% increase year-over-year.
- Alkermes plc. selling and marketing expense for the quarter ending 2025-12-31 was $120.27M, a 21.62% increase year-over-year.
- Alkermes plc. selling and marketing expense for the quarter ending 2025-09-30 was $115.63M, a 13.31% increase year-over-year.
- Alkermes plc. selling and marketing expense for fiscal 2025 was $480.01M, a 7.57% increase from fiscal 2024.
- Alkermes plc. selling and marketing expense for fiscal 2024 was $446.21M, a 8.96% decline from fiscal 2023.
- Alkermes plc. selling and marketing expense for fiscal 2023 was $490.15M, a 24.97% increase from fiscal 2022.
- Alkermes plc. selling and marketing expense for fiscal 2022 was $392.21M.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $154.36M 10-Q · filed 2026-07-28 | $309.28M 10-Q · filed 2026-07-28 | $430.20M derived: sum of 3 quarters · filed 2026-07-28 | $545.83M derived: sum of 4 quarters · filed 2026-07-28 |
| 2026-03-31 | $155.56M 10-Q · filed 2026-05-05 | $275.83M derived: sum of 2 quarters · filed 2026-05-05 | $391.46M derived: sum of 3 quarters · filed 2026-05-05 | $512.64M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-12-31 | $120.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $235.90M derived: sum of 2 quarters · filed 2026-02-25 | $357.08M derived: sum of 3 quarters · filed 2026-07-28 | $480.01M 10-K · filed 2026-02-25 |
| 2025-09-30 | $115.63M 10-Q · filed 2025-10-28 | $236.81M derived: sum of 2 quarters · filed 2026-07-28 | $359.74M 10-Q · filed 2025-10-28 | $458.63M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-06-30 | $121.17M 10-Q · filed 2026-07-28 | $244.11M 10-Q · filed 2026-07-28 | $343.00M derived: sum of 3 quarters · filed 2026-07-28 | $445.04M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-03-31 | $122.93M 10-Q · filed 2026-05-05 | $221.82M derived: sum of 2 quarters · filed 2026-05-05 | $323.86M derived: sum of 3 quarters · filed 2026-05-05 | $443.53M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $98.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $200.93M derived: sum of 2 quarters · filed 2026-02-25 | $320.60M derived: sum of 3 quarters · filed 2026-02-25 | $446.21M 10-K · filed 2026-02-25 |
| 2024-09-30 | $102.04M 10-Q · filed 2025-10-28 | $221.71M derived: sum of 2 quarters · filed 2025-10-28 | $347.33M 10-Q · filed 2025-10-28 | |
| 2024-06-30 | $119.67M 10-Q · filed 2025-07-29 | $245.28M 10-Q · filed 2025-07-29 | ||
| 2024-03-31 | $125.62M 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | $490.15M 10-K · filed 2026-02-25 | |||
| 2022-12-31 | $392.21M 10-K · filed 2025-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |